Indivior
Focus: Indivior is a UK-based specialty pharmaceutical company focused on addiction treatment, with a dominant portfolio centered on buprenorphine-based therapies for opioid use disorder. The company derives 72% of revenue from SUBOXONE, establishing it as a niche, high-concentration player in the neurology/addiction space.
Profile data last refreshed 18h ago · AI intelligence enriched 1w ago
Open Jobs
0
About Indivior
AI assessmentNot HiringNo open roles listed right now. Follow Indivior to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Late-stage
8 Phase 3+
LOE Risk
1 imminent
PERSERIS KIT
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$95M Part DDeclining
Peak
Help build intelligence for Indivior
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.